Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Completes the Acquisition of NewLab BioQuality AG

WILMINGTON, Mass.--(BUSINESS WIRE)--Sept. 9, 2008--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the acquisition of privately-held NewLab BioQuality AG (NewLab), a Dusseldorf, Germany-based provider of safety and quality control services to biopharmaceutical clients. NewLab joins Charles River Biopharmaceutical Services, which provides services to support the development and manufacture of biologics.

James C. Foster, Chairman, President and Chief Executive Officer of Charles River said, "The acquisition of NewLab further strengthens our portfolio of essential products and services to help our clients accelerate drug development. NewLab enhances the scientific depth, geographic scope and client base of Charles River's global biopharmaceutical services offering to support the rapidly growing market for biologic drug compounds. We are pleased to welcome NewLab BioQuality to the Charles River family."

About Charles River

Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our more than 8,800 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

CONTACT: Investor Contact:
Susan E. Hardy, 781.222.6190
Corporate Vice President, Investor Relations
or
Media Contact:
Charles River
Amy Cianciaruso, 781.222.6168
Associate Director, Public Relations

SOURCE: Charles River Laboratories International, Inc.

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)